ScreenerHero

VCYT Veracyte, Inc.

NAS · US · Healthcare · Diagnostics & Research · veracyte.com
47.67USD+4.06%Mkt Cap: 3.83B $P/E: 34.05

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for …

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$250.23BUSDP/E 36.4
DHR
Danaher Corporation
$155.51BUSDP/E 39.4
NTRA
Natera, Inc.
$61.35BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc.
$48.29BUSDP/E 33.8
ILMN
Illumina, Inc.
$44.35BUSDP/E 54.8
IQV
IQVIA Holdings Inc.
$43.80BUSDP/E 33.1
WAT
Waters Corporation
$43.21BUSDP/E 111.4
IDXX
IDEXX Laboratories, Inc.
$41.58BUSDP/E 37.0
MTD
Mettler-Toledo International Inc.
$30.89BUSDP/E 34.7
DGX
Quest Diagnostics Incorporated
$25.63BUSDP/E 24.7
GH
Guardant Health, Inc.
$25.12BUSD
LH
Labcorp Holdings Inc.
$25.03BUSDP/E 25.5
RVTY
Revvity, Inc.
$17.56BUSDP/E 75.3
MEDP
Medpace Holdings, Inc.
$17.32BUSDP/E 36.4
CRL
Charles River Laboratories International, Inc.
$14.84BUSD
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
ICLR
ICON Public Limited Company
$12.99BUSDP/E 177.2
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V.
$9.46BUSDP/E 23.2

Key Statistics

Company
Market Cap3.83B USD
Enterprise Value3.24B USD
Revenue (TTM)561.90M USD
Gross Profit362.53M USD
Net Income (TTM)66.35M USD
Revenue/Share7.08 USD
Last Price47.67 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees755
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)34.05
P/E (Forward)23.48
PEG—
EV/EBITDA28.52
EV/Revenue5.76
P/S6.55
P/B2.65
EPS (TTM)1.40
EPS (Forward)1.95
52W Range
29.4558% of range60.91
52W High60.91 USD
52W Low29.45 USD
Profitability
Gross Margin70.10%
Oper. Margin15.29%
EBITDA Margin20.20%
Profit Margin12.83%
ROE5.07%
ROA4.72%
Growth
Revenue Growth15.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF136.31M USD
CapEx (TTM)9.68M USD
FCF Margin18.91%
FCF Yield2.77%
Net Debt-445.13M USD
Net Debt/EBITDA-3.92
Balance Sheet
Debt/Equity0.03
Current Ratio9.16
Quick Ratio8.60
Book Value/Sh17.28 USD
Cash/Share6.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)58.42 USD
Upside (mean)+22.5%
Target Range44.00 USD – 70.00 USD
44.00+22.5% to mean70.00
# Analysts12
Ownership
Shares Out.80.39M
Float79.88M
Insiders0.49%
Institutions112.29%
Short Interest
Short Ratio6.7d
Short % Float12.35%
Short % Out.10.45%
Shares Short8.40M
Short (prev mo.)6.79M
Technical
SMA 5044.95 (+6.1%)
SMA 20042.51 (+12.1%)
Beta1.93
S&P 52W Chg14.58%
Avg Vol (30d)1.41M
Avg Vol (10d)1.60M
Technical Indicators
RSI (14)56.9
MACD0.1143
MACD Signal-0.5707
MACD Hist.+0.6850
BB Upper48.73 USD
BB Middle43.93 USD
BB Lower39.13 USD
BB Width21.87%
ATR (14)2.507 USD
Vol Ratio (20d)0.92x